5-Azacytidine treatment inhibits the development of lung cancer models via epigenetic reprogramming and activation of cellular pathways with anti-tumor activity
The combination of 5-Aza and IR shows promise as an effective treatment for NSCLC, enhancing apoptosis and reducing tumor growth through epigenetic modulation.
Authors
- Tudor–Eliade Ciuleanu (ORCID: https://orcid.org/0000-0003-0958-5597)
- Alin Moldovan (ORCID: https://orcid.org/0000-0001-7159-6102)
- Alexandra Preda
- Richard Feder
- Diana Gulei (ORCID: https://orcid.org/0000-0002-3030-8626)
- Cristian Moldovan (ORCID: https://orcid.org/0000-0003-2927-4622)
- Rareş Drulă (ORCID: https://orcid.org/0000-0001-7815-2766)
- Lajos Ráduly (ORCID: https://orcid.org/0000-0002-3926-5423)
- Adrian Bogdan Țigu (ORCID: https://orcid.org/0000-0001-9397-0791)
- Lorand Magdo
- Ancuța Jurj (ORCID: https://orcid.org/0000-0001-7653-0620)
- Radu Pîrlog (ORCID: https://orcid.org/0000-0003-2026-5543)
- Elena Ioana Braicu (ORCID: https://orcid.org/0000-0001-5357-6001)
- Raluca Munteanu (ORCID: https://orcid.org/0000-0003-0617-2084)
- Liviuţa Budişan (ORCID: https://orcid.org/0000-0001-5725-662X)
- V.C. Munteanu (ORCID: https://orcid.org/0000-0003-3808-2446)
- Mihai Romitan
- Alina‐Andreea Zimța (ORCID: https://orcid.org/0000-0003-3856-3784)
Institutions
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Institute of Oncology Prof. Dr. Ion Chiricuta (RO)
Publication Details
- Journal
- Medicine and Pharmacy Reports
- Published
- 2024-09-23
- DOI
- https://doi.org/10.15386/mpr-2777
- Citations
- 3
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.70